- Home
- News
- Treatment & Care
- HIV Worldwide
- Living with HIV
- Preventing HIV
- Organisations
- HIV Basics
- About Us
information for people living and working with HIV
HIV Worldwide
-
Adherence
-
Children
-
Clinical reviews
-
Drug supply
-
Guidelines
-
Hepatitis and HIV coinfection
-
HIV Testing
-
Infant feeding
-
Laboratory monitoring
-
Malaria & HIV
-
Mental health and HIV
-
Neurological problems, including HIV dementia
-
Nutrition
-
Palliative care
-
Prevention
-
Prevention of mother-to child transmission
-
Scaling up treatment and models of service delivery
-
Side-effects
-
South Africa
-
Starting treatment
- Switching from efavirenz to nevirapine in women with higher CD4 counts - 07/05/09
- Universal testing and immediate treatment could cut HIV infections by 95% in 10 years - 27/11/2008
- First-line antiretroviral therapy: not as simple as we'd like it to be - 19/06/08
- How to deliver good adherence support: lessons from round the world - 10/9/2007
- WHO to monitor ARV side-effects worldwide - 11/9/2007
- First-line treatment choices proving challenging for African ART programmes - 11/9/2007
- A follow-up on follow-up: shifting to a community-based response to improve retention in care - 31/8/2007
- Patient retention challenges and the need for more active follow-up - 22/3/2007
- Lowering the threshold - Is there a case for re-evaluating eligibility criteria for ART? - 1/11/2006
- Treatment equity in practice: how scarce resources for treatment are being used, and the ethical dilemmas that need to be debated - Part One - 27/10/2005
- Treatment equity in practice: how scarce resources for treatment are being used, and the ethical dilemmas that need to be debated - Part Two - 27/10/2005
- Immune reconstitution inflammatory syndrome (IRIS) in the developing world - 27/10/2005
- Symptoms versus laboratory monitoring as criteria for starting treatment - 27/10/2005
- Fixed-dose ARV combinations: choices and challenges - 27/10/2005
- Monitoring ARV treatment - 27/10/2005
- Combining ARVs with treatment for tuberculosis - 27/10/2005
- Nevirapine-based fixed-dose combination ARVs - 27/10/2005
- Co-trimoxazole prophylaxis - 27/10/2005
-
Stigma
-
Task shifting
-
Treatment failure
-
Tuberculosis
-
Viral load testing
feedback
Give us your views on our work
Starting treatment
-
Switching from efavirenz to nevirapine in women with higher CD4 counts - 07/05/09
-
Universal testing and immediate treatment could cut HIV infections by 95% in 10 years - 27/11/2008
-
First-line antiretroviral therapy: not as simple as we'd like it to be - 19/06/08
-
How to deliver good adherence support: lessons from round the world - 10/9/2007
-
WHO to monitor ARV side-effects worldwide - 11/9/2007
-
First-line treatment choices proving challenging for African ART programmes - 11/9/2007
-
A follow-up on follow-up: shifting to a community-based response to improve retention in care - 31/8/2007
-
Patient retention challenges and the need for more active follow-up - 22/3/2007
-
Lowering the threshold - Is there a case for re-evaluating eligibility criteria for ART? - 1/11/2006
-
Treatment equity in practice: how scarce resources for treatment are being used, and the ethical dilemmas that need to be debated - Part One - 27/10/2005
-
Treatment equity in practice: how scarce resources for treatment are being used, and the ethical dilemmas that need to be debated - Part Two - 27/10/2005
-
Immune reconstitution inflammatory syndrome (IRIS) in the developing world - 27/10/2005
-
Symptoms versus laboratory monitoring as criteria for starting treatment - 27/10/2005
-
Fixed-dose ARV combinations: choices and challenges - 27/10/2005
-
Monitoring ARV treatment - 27/10/2005
-
Combining ARVs with treatment for tuberculosis - 27/10/2005
-
Nevirapine-based fixed-dose combination ARVs - 27/10/2005
-
Co-trimoxazole prophylaxis - 27/10/2005
About HATIP
A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.
Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.
Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.
latest aidsmap news
- HIV/TB epidemic in Eastern Europe a 'public health disaster'
- Low bone mineral density common in HIV-positive men
- Circumcision may protect HIV-negative gay men from syphilis
- HIV 'exposure' from bite forms basis for terrorism charge in US case
- First hint of a hepatitis C vaccine?
- Pregnancy, not nevirapine cause of liver toxicities in HIV-positive women
- Surviving to die of something else: AIDS is a rare cause of death in old people with HIV
- New EACS guidelines address co-morbidities and diseases of age
- Small case series looks at etravirine during pregnancy
- Protease inhibitor monotherapy as a maintenance regimen: are we edging towards acceptance?